Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors

BMC Neurology

Table 3 Determinants of progression-free survival after PCV (n = 59) and PC (n = 83) treatment in patients with complete data (100 events)

		Hazard ratio*	95% confidence interval	p value
Treatment	PCV vs. PC	0.81	0.53–1.25	0.346
Age (in years)	< 50 vs. ≥50	0.64	0.41–1.00	0.051
Resection before chemotherapy	yes vs. no	1.61	1.01–2.58	0.047
Histology	Oligoastrocytoma vs oligodendroglioma	1.34	0.83–2.18	0.487
	Other vs oligodendroglioma	1.42	0.46–4.39
WHO grade	II vs III/IV	0.75	0.49–1.14	0.176
Karnofsky performance score	< 90 vs ≥90	1.26	0.81–1.96	0.304

* A hazard ratio < 1 (> 1) indicates an effect in favor of the first (the second) group in terms of progression-free survival.

ISSN: 1471-2377